RxDoctor Payments Data

Ladonna Cook

Nurse Practitioner · Winston Salem, NCNPI 1265407605

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $21,765 of the $23,015 with a category attached, or 94.6%. AbbVie accounts for 83.7% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2022 at $18,218 and has fallen 99.8% since, to $36 in 2024. Among nurse practitioner clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$23,015in general payments, 2019–2025

Across 57 payments — averaging $403.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$19K
  • Biohaven Pharmaceutical Holding Company Ltd.$3K
  • Impel Pharmaceuticals Inc.$477
  • Teva Pharmaceuticals USA, Inc.$120
  • Haemonetics Corporation$36

What the payments were for

  • Consulting fees$4772%
  • Speaking & faculty fees$21,76595%
  • Food & beverage$7733%

General payments by program year

21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,015 in reported general payments places this provider in the 95th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$7,345
Medicare patients
42
Services billed
57

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aimovig AutoinjectorErenumab-Aooe99$97,540
UbrelvyUbrogepant35$47,337
Emgality PenGalcanezumab-Gnlm40$32,614
Zonisamide11$514
Topiramate45$471
RizatriptanRizatriptan Benzoate35$343
Sumatriptan Succinate43$327
Cyclobenzaprine Hcl14$285
Baclofen19$250
Amitriptyline Hcl13$244
Ondansetron Hcl15$236
Gabapentin11$189
Duloxetine Hcl11$181

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$19,264$47,33735 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Winston Salem

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →